These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36120536)

  • 1. Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma.
    Zhao L; Luo T; Jiang J; Wu J; Zhang X
    Front Mol Biosci; 2022; 9():1001792. PubMed ID: 36120536
    [No Abstract]   [Full Text] [Related]  

  • 2. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
    Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
    Front Immunol; 2022; 13():991091. PubMed ID: 36248841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.
    Andrews MC; Li G; Graf RP; Fisher VA; Mitchell J; Aboosaiedi A; O'Rourke H; Shackleton M; Iddawela M; Oxnard GR; Huang RSP
    JCO Precis Oncol; 2024 Jun; 8():e2300640. PubMed ID: 38848517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
    Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
    Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Ma SC; Zhu HB; Wang J; Zhang YP; Guo XJ; Long LL; Guo ZQ; Wu DH; Dong ZY; Bai X
    Front Oncol; 2021; 11():666145. PubMed ID: 34221982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma.
    Chen M; Li P; Yao H; Liu F; Fu L; Wang Y; Zhu J; Xu Q; Liang H; Zhou Y; Wang Z; Deng Q; Chen W; Cao J; Chen X; Luo J
    Transl Androl Urol; 2023 Mar; 12(3):406-424. PubMed ID: 37032757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
    Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
    JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
    Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study.
    Safi M; Jin C; Aldanakh A; Feng P; Qin H; Alradhi M; Zhang L; Zhang J; Adlat S; Zhao Y; Liu J
    BMC Cancer; 2022 Sep; 22(1):978. PubMed ID: 36100891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.
    Zhang W; Tang Y; Guo Y; Kong Y; Shi F; Sheng C; Wang S; Wang Q
    NPJ Precis Oncol; 2022 Jun; 6(1):46. PubMed ID: 35739249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors.
    Liu Y; Chen L; Zhang S; Shu Y; Qi Q; Zhu M; Peng Y; Ling Y
    Oncol Lett; 2020 Oct; 20(4):27. PubMed ID: 32774500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
    Kelly D; Rose AAN; Muniz TP; Hogg D; Butler MO; Saibil SD; King I; Kamil ZS; Ghazarian D; Ross K; Iafolla M; Araujo DV; Waldron J; Laperriere N; Krema H; Spreafico A
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma.
    Patterson A; Auslander N
    Nat Commun; 2022 Sep; 13(1):5151. PubMed ID: 36123351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the survival of adult patients with metastasized melanoma with the approval of immune checkpoint inhibitors: A retrospective study from the United States database.
    Adhikari A; Cha E; Antala D; Sapkota S; Bhattarai U
    Cancer Epidemiol; 2022 Dec; 81():102254. PubMed ID: 36162155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
    Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
    Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.